Sutrip Dosage/Direction for Use

It may be given orally or subcutaneously as the succinate and intranasally as the base. Doses are expressed in terms of the base; sumatriptan succinate 70 mg is equivalent to about 50 mg of sumatriptan. For the acute treatment of migraine sumatriptan should be used as soon as possible after the onset of the headache phase, but efficacy is independent of the duration of the attack before starting treatment. If no response is obtained with the initial dose by any route, a second dose should not be given for the same attack.
It is given orally to adults aged 18 years and over, the clinical response can be expected after about 30 minutes. If symptoms recur after an initial response, further doses may be given provided that there is a minimum interval of 2 hours between doses and that not more than 300 mg is taken in any 24-hour period. A lower dose of 25 mg may be used, although some patients require 50 or 100 mg.
This may be followed by a second dose of up to 100 mg if the headache returns or the patient has a partial response provided that the total daily dose does not exceed the recommended maximum of 200 mg. A minimum interval of 2 hours is recommended between doses or as prescribed by the physician.
Administration in children: Sumatriptan may be given for the treatment of acute migraine in children and adolescents. Although not licensed for oral paediatric a single oral dose of 25 mg may be given to children aged 6 to10 years and 50 mg to those aged 10 to 12 years, repeated once after at least 2 hours if symptoms recur after an initial response; older children may be given the usual adult dose.
Administration in hepatic impairment: A dose of up to 50 mg by mouth is considered suitable. It should not be given to patients with severe impairment.
For High-altitude disorders, Sumatriptan has been tried with some success in a small study for the prevention of symptoms of acute mountain sickness.